ProVate Vaginal Support

K190277 · Contipi Medical , Ltd. · HHW · Jul 8, 2019 · Obstetrics/Gynecology

Device Facts

• Record ID: K190277
• Device Name: ProVate Vaginal Support
• Applicant: Contipi Medical , Ltd.
• Product Code: HHW · Obstetrics/Gynecology
• Decision Date: Jul 8, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 884.3575
• Device Class: Class 2
• Attributes: Therapeutic

Indications for Use

The ProVate Vaginal Support is indicated for the temporary, nonsurgical management of Pelvic Organ Prolapse in females.

Device Story

ProVate Vaginal Support is a disposable, single-use ring pessary for temporary, nonsurgical management of Pelvic Organ Prolapse (POP). Device supplied in compact mode within a single-use applicator; physician performs initial size fitting. Patient inserts device using applicator, which expands ring to support prolapsed organs. Device worn for up to 7 days; patient removes by pulling a string, which collapses device into compact state for easy extraction. Used in home environment; patient-operated after professional fitting. Provides mechanical support to prolapsed organs; improves prolapse stage (e.g., from stage 2/3 to 0/1) and symptoms. Benefits include conservative, temporary management of POP without surgery.

Clinical Evidence

Two prospective clinical studies conducted. 1) Randomized, multicenter, crossover study (n=not specified) compared ProVate to a marketed ring pessary; primary endpoint met, showing non-inferiority regarding vaginal microflora impact. 2) Prospective, one-arm, multicenter study (n=not specified) evaluated safety and effectiveness in home use; subjects with baseline stage 2-3 POP achieved stage 0-1 with device. Adverse events were mild, transient, and comparable to predicate.

Technological Characteristics

Ring-shaped vaginal pessary; dual-configuration (compact/expanded). Constructed of polymers. Single-use, disposable. Includes applicator and removal string. Biocompatibility per ISO 10993-1 (cytotoxicity, sensitization, irritation, implantation, genotoxicity). Mechanical testing includes insertion/removal force, directional compression, and string integrity.

Indications for Use

Indicated for temporary, nonsurgical management of Pelvic Organ Prolapse (POP) in females. Patient population includes those with stage 2 or 3 prolapse.

Regulatory Classification

Identification

A vaginal pessary is a removable structure placed in the vagina to support the pelvic organs and is used to treat conditions such as uterine prolapse (falling down of uterus), uterine retroposition (backward displacement), or gynecologic hernia.

Predicate Devices

• EIS Corporation, Pessary (K132313)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

July 8, 2019

ConTIPI Medical Ltd. % Jonathan Kahan Partner Hogan Lovells US LPP 555 Thirteenth Street NW Washington, DC 20004

Re: K190277

> Trade/Device Name: ProVate Vaginal Support Regulation Number: 21 CFR 884.3575 Regulation Name: Vaginal Pessary Regulatory Class: II Product Code: HHW Dated: June 7, 2019 Received: June 7, 2019

Dear Jonathan Kahan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

Sharon Andrews Assistant Division Director DHT3B: Division of Reproductive, Gynecology and Urology Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K190277

Device Name ProVate Vaginal Support

Indications for Use (Describe)

The ProVate Vaginal Support is indicated for the temporary, nonsurgical management of Pelvic Organ Prolapse in females.

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

### 510(k) SUMMARY

### ConTIPI Medical Ltd.'s ProVate Vaginal Support

### Submitter

ConTIPI Medical Ltd 2 Alon Ha'Tavor st. Caesarea Industrial Park, РОВ 3135 Caesarea, Israel Israel, 3088900

Phone: [phone] Facsimile: [phone] Contact Person: Tsvia Erlich, VP Requlatory & Clinical Affairs

Date Prepared: July 8, 2019

### Name of Device:

ProVate Vaginal Support

### Common or Usual Name:

Vaginal Pessary

# Classification Name:

Vaginal pessary (21 CFR 884.3575)

# Regulatory Class:

Class II

# Product Code:

HHW (pessary, vaginal)

### Predicate Devices

EIS Corporation, Pessary (K132313)

The predicate device has not been subject to a design related recall.

### Device Description

The ProVate Vaginal Support is a vaginal ring pessary intended for the conservative nonsurgical, temporary management of Pelvic Organ Prolapse (POP) in females. The ProVate is a disposable, single use device intended to use for up to seven (7) days. The ProVate device is intended for prescription home use following a size fitting process performed by a health care professional.

{4}------------------------------------------------

The device is supplied in its compact mode, within a disposable Applicator intended for the insertion of the device is expanded into its circular ring shape using the Applicator Plunger when inserting the device into the vagina. At the end of its use (up to 7 days), the patient pulls the Removal String which collapses the device into its compact configuration, facilitating easy removal. The device is then thrown away, and a new device can be inserted by the patient as needed.

The ProVate includes additional components to facilitate insertion and removal of the device. The ProVate device is constructed to allow insertion into the vagina by the patient while the device is in a compact mode contained within a single use applicator. The ProVate device is expanded to its circular shape using the applicator when inserted into the vagina. Once inserted, the circular shape of the ProVate is comparable to that of the predicate device and the ring provides support to the prolapsed organs. To remove the device, the ProVate includes a removal string. Pulling on the string collapses the device to its compact state allowing for easier and more comfortable removal.

#### Intended Use / Indications for Use

The ProVate Vaginal Support is indicated for the temporary, nonsurgical management of Pelvic Organ Prolapse in females.

#### Comparison of Technological Characteristics with the Predicate Device

The ProVate device is a ring vaginal pessary that is used to provide support to prolapsed organs, in a similar manner to the predicate. Both the ProVate pessary and the predicate pessary are ring shaped and are available in multiple sizes.

The main differences between the subject and predicate devices are:

- The predicate device is made of flexible materials (silicone) which allow . the form to be moderately manipulated. while the subject device uses different polymer materials. However, the predicate does not incorporate the dual configuration design (collapsed and expanded state) of the subject device.
- The subject device is intended to be inserted and removed by the user in the home, while the predicate device is to be inserted initially by a physician with optional patient removal in the home following the initial use.
- . The subject device is single use for up to 7 days (no cleaning) while the predicate is reusable with cleaning instructions.

These differences do not raise different questions of safety or effectiveness, and accepted test methods (e.g., biocompatibility, mechanical testing, vaginal microflora testing, and clinical testing) exist to assess the effects of these differences on device performance.

{5}------------------------------------------------

### Performance Data

The following testing was conducted to evaluate the properties and performance of the device to confirm that the device meets its specifications:

- Bench testing was performed to confirm that the device met key . performance specifications related to the functionality and safety of the device, such as, insertion and removal, device's and removal string's integrity, maximal forces, etc. The testing included the following:
- Insertion Force O
- Removal Force O
- Directional compression o
- Repeatable directional compression O
- Extreme compression O
- Load on central Axis o
- String Detachment Force о
- o Removal String Integrity
- . Shelf life study to support two (2) years shelf life of theproduct
- . Biocompatibility testing and chemical characterization of the device materials according to ISO 10993-1 and applicable FDA guidance documents. The following biocompatibility testing were conducted:

| ISO<br>Standard | Test | Results |
|-----------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| 10993-5 | Cytotoxicity Study Using the<br>ISO Elution Method | Non-cytotoxic |
| 10993-10 | ISO Guinea Pig<br>Maximization Sensitization<br>Test | Non-sensitizer |
| 10993-10 | ISO Vaginal Irritation Study<br>in Rabbits | Non-irritant |
| 10993-6 | ISO Muscle Implantation<br>Study in Rabbits - 4<br>Weeks and 10 Week | Macroscopic: Difference not<br>significant;<br>Microscopic: Non-irritant |
| 10993-3 | Genotoxicity: Bacterial<br>Reverse Mutation Study | Non-mutagenic |
| 10993-3 | Genotoxicity: Mouse<br>Lymphoma Assay | Non-mutagenic |
| 10993-18 | Toxicological Risk<br>assessment | Acceptable risk of daily dose-<br>exposure to compounds from<br>device use |

- Evaluation of TSST-1 Risk laboratory testing to evaluate the impact of the ● device on Staphylococcus aureus growth and TSST-1 production
- Human factors label comprehension validation study, by potential . representative US users intended to evaluate the safety and suitability of

{6}------------------------------------------------

device labeling.

### Clinical Testing

Two clinical studies were conducted on the ProVate device:

Prospective Safety Clinical Study. This prospective, statistically powered, multicenter, randomized, cross over study was intended to evaluate the impact of the ProVate device on vaginal microflora as compared to a control (US marketed vaginal pessary). Subjects used both the ProVate device and the control device in a cross over fashion following a wash out period. Vaginal examination and microbial evaluations were performed at the beginning and at the end of each usage phase (ProVate device and control). Safety was also assessed by an evaluation of adverse events. All study endpoints were met successfully. The primary endpoint in this study was met successfully showing non-inferiority of the ProVate Device with respect to changes in vaqinal microflora when compared to an existing market available ring pessary. There was no device related serious adverse events. The majority of the adverse events were considered minor, transient and resolved with no sequalae.

Prospective Clinical Study to Evaluate Safety and Effectiveness. A statistically powered, one arm, multi clinic prospective study was performed to evaluate the safety and performance of the ProVate device. Following a fitting process performed by a physician, users used devices within their home environment. The study device was used in a home use environment and followed the clinical routine for the management of pessaries. Vaginal examinations were conducted during each visit to the study clinic.

The study demonstrated that the device resulted in an improvement from baseline of at least one stage in prolapse and an improvement in prolapse symptoms while in use. Subjects started with stage 2 or 3 level prolapse at baseline and had stage 0 or 1 prolapse with the device in place.

In addition, the device did not result in adverse events at a higher rate than that of predicate pessary devices. All device-related adverse events were mild and transient.

#### Conclusions

The performance data demonstrate that the ProVate is as safe and effective as the EIS Corporation Pessary predicate device.